<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B66B6A4F-3756-450B-A344-FF2874C7BEFE"><gtr:id>B66B6A4F-3756-450B-A344-FF2874C7BEFE</gtr:id><gtr:name>Absynth Biologics Limited</gtr:name><gtr:address><gtr:line1>BIOHUB AT ALDERLEY PARK , ALDERLEY PARK</gtr:line1><gtr:city>MACCLESFIELD</gtr:city><gtr:postCode>SK10 4TG</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B66B6A4F-3756-450B-A344-FF2874C7BEFE" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>B66B6A4F-3756-450B-A344-FF2874C7BEFE</gtr:id><gtr:name>Absynth Biologics Limited</gtr:name><gtr:address><gtr:line1>BIOHUB AT ALDERLEY PARK , ALDERLEY PARK</gtr:line1><gtr:city>MACCLESFIELD</gtr:city><gtr:postCode>SK10 4TG</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>25000.0</gtr:offerGrant><gtr:projectCost>41797.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700096"><gtr:id>A3B8CD2A-AECE-497B-A53F-2DD900166025</gtr:id><gtr:title>Bacterial Vaccines and Therapies - Building a Product Pipeline</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700096</gtr:grantReference><gtr:abstractText>Absynth Biologics has successfully demonstrated an innovative approach for developing new
antibacterial vaccines and antibodies. Absynth?s technology identifies proteins, essential for
the life of bacteria that harness the immune system. To date the Company has shown its
approach can protect against infections caused by a major pathogen Staphylococcus aureus (S.
aureus), including antibiotic resistant variety MRSA (Methicillin Resistant S. aureus). The
Absynth anti-S.aureus vaccine and antibodies are being advanced in pre-clinical development.
A central aspect of the Absynth technology is the degree of conservation of these proteins
across the bacterial kingdom. Consequently the same targets found in S. aureus also are
present in many other bacterial pathogens. With this proprietary knowledge Absynth can
rapidly initiate new vaccine and antibody programmes to develop a product pipeline.
The objective of this project is to assess the broader market needs to prevent and treat
bacterial infections, addressable by Absynth?s technology. With a clear understanding of
unmet customer/patient needs, market size, drivers, dynamics and competition, Absynth will
be able to select those opportunities to build a pipeline.
Resistance to antibiotics in increasing at an alarming rate, driving the need for antibacterial
vaccines and antibodies. The market for bacterial vaccines is expected to grow from $3.9
billion to $15.5 billion by 2014 and there is growing interest in anti-infective antibody
products with only one, Synagis, licensed for use.
There currently are no marketed S. aureus vaccines or antibodies and the sales potential is
estimated to be &amp;gt;US $2 billion. Many other bacterial infections lack vaccines or antibodies
including hospital infections cause by C. difficile, sexually transmitted diseases caused by N.
gonorrhoea and community-based infections caused by E. coli. The new opportunities for
Absynth are significant.</gtr:abstractText><gtr:fund><gtr:end>2012-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>25000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700096</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>